Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 6, 1996, Pages 862-869

  Vemulapalli, Subbarao ^a   Watkins, Robert W ^a   Chintala, Madhu ^a   Davis, Harry ^a   Ahn, Ho Sam ^a   Fawzi, Ahmad ^a   Tulshian, Deen ^a   Chiu, Peter ^a   Chatterjee, Meeta ^a   Lin, Chin Chung ^a   Sybertz, Edmund J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antiplatelet; E4021; Neointima; Phosphodiesterase inhibition; SCH 51866

Indexed keywords

1 [6 CHLORO 4 (3,4 METHYLENEDIOXYBENZYLAMINO) 2 QUINAZOLINYL] 4 PIPERIDINECARBOXYLIC ACID; ANTITHROMBOCYTIC AGENT; COLLAGEN; ORG 20241; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; SCH 51866; UNCLASSIFIED DRUG; ZAPRINAST;

ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTERY THROMBOSIS; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RAT; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; ARTERIES; BLOOD PLATELETS; CATTLE; CELL DIVISION; DOGS; ENZYME INHIBITORS; HUMANS; HYPERTENSION; IMIDAZOLES; NUCLEOTIDES, CYCLIC; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERIDINES; PLATELET AGGREGATION INHIBITORS; QUINAZOLINES; RATS; RATS, INBRED SHR;

EID: 10544224533     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199612000-00018     Document Type: Article

References (37)

1. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 1986;78:1-5.
2. Kariya K-I, Kawahara Y, Araki S-I, Fukuzaki H, Takai Y. Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic muscle cells. Atherosclerosis 1989;80:143-7.
3. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;2:1057-8.
4. Siney L, Lewis MJ. Endothelium-derived relaxing factor inhibits platelet adhesion to cultured porcine endocardial endothelium. Eur J Pharmacol 1990;229:223-6.
5. Venturini CM, Weston LK, Kaplan JE. Platelet cGMP, but not cAMP, inhibits thrombin-induced platelet adhesion to pulmonary vascular endothelium. Am J Physiol 1992;262:H606-12.
6. Radomski MW, Palmer RMJ, Moncada S. Characterization of the L-arginine:nitric oxide pathway in human platelets. Br J Pharmacol 1990;101:325-8.
7. Vemulapalli S, Chiu PJS, Kurowski S, Brown A, Hartman BA, Leach MW. In vivo inhibition of platelet adhesion by a cGMP-mediated mechanism in balloon catheter injured rat carotid artery. Pharmacology 1996;52:235-42.
8. Beavo JA, Reifsnyder DH. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 1990;11:150-5.
9. Beavo JA, Conti M, Heaslip R. Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 1994;46:399-405.
10. Nicholson CD, Challiss RAJ, Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 1991;12:19-27.
11. Silver PJ, Pagani ED. Biochemical and preclinical pharmacology of selective inhibitors of cardiovascular phosphodiesterase isozymes. In: Gwathmey JK, Briggs GM, Allen PD, eds. Heart failure: basic science and clinical aspects. New York: Marcel Dekker, 1993:367-86.
12. Goldstein RA, Fleming RM. Clinical aspects of phosphodiesterase inhibitors. In: Gwathmey JK, Briggs GM, Allen PD, eds. Heart failure: basic science and clinical aspects. New York: Marcel Dekker, 1993:387-98.
13. Nicholson CD, Shahid M, Bruin J, et al. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor in asthma. J Pharmacol Exp Ther 1995;274:678-87.
14. Saeki T, Adachi H, Takase Y, Yoshitake S, Souda S, Saito I. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. J Pharmacol Exp Ther 1995;272:825-31.
15. Ahn HS, Crim W, Romano M, Sybertz E, Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol 1989;38:3331-9.
16. Radomski M, Moncada S. An improved method for washing of human platelets with prostacyclin. Thromb Res 1983;30:383-9.
17. Reidy MA, Yoshida K, Harker LA, Schwartz SM. Vascular injury: quantification of experimental focal endothelial denudation in rats using indium-111-labeled platelets. Arteriosclerosis 1986;6:305-11.
18. Watanabe H, Kakihana M, Ohtsuka S, et al. Platelet cGMP: a potentially useful indicator to evaluate the effects of nitroglycerin and nitrate tolerance. Circulation 1993;88:29-36.
19. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest 1983;49:208-15.
20. Labarca C, Paigen KA. A simple, rapid and sensitive DNA assay procedure. Anal Biochem 1980;102:344-52.
21. Anderson TLG, Vinge E. Interactions between isoprenaline, sodium nitroprusside, and isozyme-selective phosphodiesterase inhibitors on ADP-induced aggregation and cyclic nucleotide levels in human platelets. J Cardiovasc Pharmacol 1991;18:237-42.
22. Dohi M, Sakata Y, Seki J, et al. The anti-platelet actions of FR 122047, a novel cyclooxygenase inhibitor. Eur J Pharmacol 1993;243:179-84.
23. Groves PH, Penny WH, Cheadle HA, Lewis MA. Exogenous nitric oxide inhibits in vivo platelet adhesion following balloon angioplasty. Cardiovasc Res 1992;26:65-8.
24. Chintala MS, Bernardino V, Chiu PJS. Cyclic GMP but not cyclic AMP prevents renal platelet accumulation after ischemia-reperfusion in anesthetized rats. J Pharmacol Exp Ther 1994;271:1203-8.
25. Lieberman EH, O'Neil S, Mendelsohn ME. S-nitrosocystein inhibition of human platelet secretion is correlated with increases in platelet cGMP levels. Circ Res 1991;68:1722-8.
26. Mendelsohn ME, O'Neil S, George D, et al. Inhibition of fibrinogen binding to human platelets by S-nitroso-N-acetylcysteine. J Biol Chem 1990;265:19028-34.
27. Barnathan ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987;76:125-34.
28. Lembo NJ, Black AJ, Roubin GS, et al. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990;65:422-6.
29. Frishman WH, Burns B, Atac B, et al. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 1995;130:877-92.
30. Tcheng JE. Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. Am Heart J 1995;130:673-9.
31. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-Br-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;13:1874-84.
32. Guo J, Milhoan KA, Tuan RS, Lefer AM. Beneficial effect of SPM-5185, a cysteine-containing nitric oxide donor, in rat carotid artery intimal injury. Circ Res 1994;75:77-84.
33. De Meyer GRY, Bult H, Ustunes L, et al. Effect of nitric oxide donors on neointima formation and vascular reactivity in the collared carotid artery of rabbits. J Cardiovasc Pharmacol 1995;26:272-9.
34. Watkins RW, Davis HR, Fawzi A, et al. Antihypertensive, hemodynamic and vascular protective effects of SCH 51866, an inhibitor of cGMP hydrolysis [Abstract]. Fed Am Soc Exp Biol 1995;9:A342.
35. Lam JYT, Lacoste L, Bourassa M. Cilazapril and early atherosclerotic changes after balloon injury of porcine carotid arteries. Circulation 1992;85:1542-7.
36. Powell JS, Muller RKM, Baumgartner HR. Suppression of the vascular response to injury: the role of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 1991;17:137-42b.
37. Charterjee M, Davis HR, Watkins RW, et al. The inhibition of myointimal proliferation by selective inhibition of cGMP phosphodiesterases (PDEs) [Abstract]. Circulation 1994;90:I-627.